Jemperli is currently approved or being developed in markets where there are opportunities for transformational outcomes
1. Not-exhaustive; 2. Registrational studies also ongoing in China and Japan; 3. HSNCC - Head and neck squamous cell carcinomas; 4. Per clinicaltrials.gov estimated primary completion date; 5. GSK Q4 2025 earnings
